Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bingming Yi

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Current Medical Research and Opinion|October 7, 2006
Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetesGary A Herman, Arthur Bergman, Bingming Yi, et al.
Journal of Chemical Information and Computer Sciences|October 16, 2002
A factorial design to optimize cell-based drug discovery analysisBingming Yi, Jacqueline M Hughes-Oliver, Lei Zhu, et al.
Journal of Biopharmaceutical Statistics|August 1, 2025
Weighted sum and order statistics methods for dynamic information borrowing in basket trialsCheng Huang, Chenghao Chu, Yimeng Lu, et al.
Journal of Biopharmaceutical Statistics|March 29, 2023
A confirmatory basket design considering non-inferiority and superiority testingYaohua Zhang, Chenghao Chu, Robert A Beckman, et al.
Advances in Therapy|April 10, 2019
Indirect Comparison of Ropinirole and Pramipexole as Levodopa Adjunctive Therapy in Advanced Parkinson's Disease: A Systematic Review and Network Meta-AnalysisHongxin Zhao, Yi Ning, James Cooper, et al.
British Journal of Clinical Pharmacology|February 3, 2011
Evaluation of pharmacokinetic parameters and dipeptidyl peptidase-4 inhibition following single doses of sitagliptin in healthy, young Japanese malesGary A Herman, Goutam C Mistry, Bingming Yi, et al.
Clinical Pharmacology and Therapeutics|December 13, 2005
Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral dosesGary A Herman, Cathy Stevens, Kristien Van Dyck, et al.
Clinical Therapeutics|February 24, 2006
Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteersArthur J Bergman, Catherine Stevens, YanYan Zhou, et al.
Bone|September 30, 2009
An orally active calcium-sensing receptor antagonist that transiently increases plasma concentrations of PTH and stimulates bone formationSanjay Kumar, Christopher J Matheny, Sandra J Hoffman, et al.
The Journal of Clinical Endocrinology and Metabolism|August 17, 2006
Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetesGary A Herman, Arthur Bergman, Catherine Stevens, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Current Medical Research and Opinion|October 7, 2006
Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetesGary A Herman, Arthur Bergman, Bingming Yi, et al.
Journal of Chemical Information and Computer Sciences|October 16, 2002
A factorial design to optimize cell-based drug discovery analysisBingming Yi, Jacqueline M Hughes-Oliver, Lei Zhu, et al.
Journal of Biopharmaceutical Statistics|August 1, 2025
Weighted sum and order statistics methods for dynamic information borrowing in basket trialsCheng Huang, Chenghao Chu, Yimeng Lu, et al.
Journal of Biopharmaceutical Statistics|March 29, 2023
A confirmatory basket design considering non-inferiority and superiority testingYaohua Zhang, Chenghao Chu, Robert A Beckman, et al.
Advances in Therapy|April 10, 2019
Indirect Comparison of Ropinirole and Pramipexole as Levodopa Adjunctive Therapy in Advanced Parkinson's Disease: A Systematic Review and Network Meta-AnalysisHongxin Zhao, Yi Ning, James Cooper, et al.
British Journal of Clinical Pharmacology|February 3, 2011
Evaluation of pharmacokinetic parameters and dipeptidyl peptidase-4 inhibition following single doses of sitagliptin in healthy, young Japanese malesGary A Herman, Goutam C Mistry, Bingming Yi, et al.
Clinical Pharmacology and Therapeutics|December 13, 2005
Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral dosesGary A Herman, Cathy Stevens, Kristien Van Dyck, et al.
Clinical Therapeutics|February 24, 2006
Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteersArthur J Bergman, Catherine Stevens, YanYan Zhou, et al.
Bone|September 30, 2009
An orally active calcium-sensing receptor antagonist that transiently increases plasma concentrations of PTH and stimulates bone formationSanjay Kumar, Christopher J Matheny, Sandra J Hoffman, et al.
The Journal of Clinical Endocrinology and Metabolism|August 17, 2006
Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetesGary A Herman, Arthur Bergman, Catherine Stevens, et al.
Pageof 1